Aristotle University Of Thessaloniki (AUTH)
Φαρμακοκινητική της δαπτομυκίνης σε ασθενείς που υποβάλλονται σε εξωνεφρική κάθαρση
Abstract
dc:descriptionPatients with End-Stage Renal Disease treated with Continuous Ambulatory Peritoneal Dialysis (CAPD) are a special population of patients, with high comorbidity and high susceptibility to infections, which are the second leading cause of mortality following cardiovascular complications. Peritoneal dialysis - related infections are categorized as catheter exit site infections, tunnel infections, and peritonitis. Peritoneal dialysis – Related Peritonitis (PDRP) is one of the most serious complications, as it causes deleterious anatomical, morphological and functional alterations of the peritoneal membrane, which can lead to catheter loss, transfer to hemodialysis, transient loss of ultrafiltration and occasionally death. PDRP is a difficult to treat infection as patients need to continue their life-saving dialysis modality at the same time. The majority of peritonitis cases are caused by gram-positive organisms, most commonly Staphylococcus spp. Staphylococcus aureus infections, especially those caused by methicillin-resistant strains (MRSA), and Enterococcus infections are responsible for the most severe and difficult to treat PDRP cases. Daptomycin is the first lipopeptidic antibiotic with excellent in vitro bactericidal activity against a large spectrum of gram-positive organisms, MRSA, VISA, and VRE included. The dosage regimen of daptomycin has not yet been determined in peritoneal dialysis patients, as there are few pharmacokinetic studies in patients with renal insufficiency and even fewer in patients undergoing peritoneal dialysis. This pharmacokinetic study of Daptomycin was conducted among nineteen CAPD patients after single dose of 6 mg/Kg BW, given intravenously in nine patients and intraperitoneally in ten patients. Blood and peritoneal fluid samples were collected at predetermined times from time zero to 48 hours after dosing in all patients. High Performance Liquid Chromatography (HPLC) was used to determine the concentrations of the study drug in plasma and peritoneal dialysate. The pharmacokinetic parameters, elimination half-life, extraction ratio and total plasma clearance, and the pharmacodynamic parameters, peritoneal penetration index for IV and IP administration, therapeutic index and inhibitory quotient, were determined, in order to provide useful information for the treatment of peritoneal dialysis related infections. The most important results and conclusions are summarized below: • The mean plasma Daptomycin concentration after IV administration at 6 hours after dosing was 19.27μg/mL, at 12 hours 15.77μg/mL, at 24 hours 10.32μg/mL and finally at 48 hours was 3.93μg/mL. Correspondingly, the mean concentration of daptomycin in peritoneal dialysate at 6 hours after dosing was 2.46μg/mL, at 12 hours 2.05μg/mL, at 24 hours 1.63μg/mL, and at 48 hours was 1.5μg/mL. The peak concentration (Cmax) of Daptomycin measured in peritoneal dialysate was 2.46μg/mL and it was achieved at 5.2 hours after IV dosing (Tmax). • The mean value for the plasma area under curve (AUC) during the 1st 24 hour period after IV administration was 401.4μg/mL.hr, during the 2nd 24 hour period was 161.7μg/mL.hr, and the value of cumulative AUC from time zero to 48 hours was 563.1μg/mL.hr. Correspondingly, the mean peritoneal dialysate AUC values were 47.8μg/mL.hr, 37.7μg/mL.hr and the cumulative AUC levels were 85.5μg/mL.hr, much lower compared to plasma values. • Comparison of Daptomycin’s mean plasma and peritoneal dialysate concentrations and the cumulative plasma and peritoneal AUC levels achieved after IV dosing indicates lower concentrations in the peritoneal cavity than in plasma. • In the CAPD patients enrolled in the study the elimination half-life, the extraction ratio and the total plasma clearance were also determined after IV administration of Daptomycin. The elimination half-life was 14.7 hours, higher than the half-life in healthy subjects (9 hours), obviously due to renal impairment. The extraction ratio (Kel) was 0.05 hrs ^ 1 and the total plasma clearance was 1.0 lit/hour, which is lower than reported for HD (2.05 lit/hour). • Daptomycin administered intraperitoneally resulted in mean plasma concentrations of 18.31μg/mL at 6 hours, 13.22μg/mL at 12 hours, 8.41μg/mL at 24 hours and 3,61μg/mL at 48 hours after dosing. The peak plasma concentration was 18.31μg/ml and it was achieved at 6.6 hours (Tmax). Correspondingly, the mean concentration of daptomycin in peritoneal dialysate was 46.81μg/mL at 6 hours, 3.51μg/mL at 12 hours, 2.59μg/mL at 24 hours, and 3.96μg/mL at 48 hours after dosing. • The mean value for the plasma area under the curve (AUC) during the 1st 24hour period after intraperitoneal dosing was 286.2μg/mL.hr, during the 2nd 24 hour period was 138.9 μg/mL.hr and the value of cumulative AUC from time zero to 48 hours was 425.0μg/mL.hr. Correspondingly, the mean peritoneal dialysate AUC values were 735.1μg/mL.hr, 63.1μg/mL.hr and the cumulative AUC levels were 798.1μg/mL.hr. • The peritoneal penetration rate after the IV Daptomycin administration was 0.14 (i.e. penetration index approximately 14%). This striking finding indicates that the peritoneal membrane has a poor permeability to Daptomycin from plasma to the peritoneal cavity, apparently due to the high protein binding (> 90%) of Daptomycin, and it was independent to the administered drug amount. This finding explains the very low peritoneal dialysate levels of Daptomycin concentrations achieved after its IV administration. In contrast, the penetration rate of Daptomycin from the peritoneal cavity to plasma, after IP dosing was 0.44 (i.e. penetration index approximately 44%), significantly higher than the observed penetration rate from plasma to peritoneal cavity, probably because Daptomycin is administered directly, as unbound drug, in peritoneal dialysate. • The observed significant difference in penetration rate following different administration routes can be used to predict the possible failure of intravenously administered daptomycin for the treatment of peritoneal dialysis-related infections due to its ineffective peritoneal tissue penetration. In contrast, it indicates the superiority of the intraperitoneal route of administration for the successful treatment of these infections. • The mean Daptomycin peritoneal dialysate concentrations as early as at six hours after IV administration were lower than the breakpoints for the majority of the selected pathogens, consisted with the very low peritoneal penetration rate, indicating that IV route of administration is ineffective for the treatment of Peritoneal Dialysis Related Peritonitis. • Daptomycin administered intraperitoneally at a dose of 6mg/mL BW resulted in plasma concentrations higher than breakpoints for all staphylococci, MRSA included, up to 24 hours after dosing and also achieved an Inhibitory Quotient (Cmax/MIC90) value higher than 36. These findings suggest that the intraperitoneal route of daptomycin administration can be used alternatively for the treatment of complicated skin and soft tissue infections and/or for systemic infections, in CAPD patients. • Daptomycin administered intraperitoneally at a dose of 6mg/mL BW resulted in much higher concentrations in peritoneal dialysate than critical concentrations for the treatment of methicillin-resistant staphylococcus aureus (MRSA), for up to 48 hours after administration, indicating its adequacy and efficacy in the treatment of MRSA peritoneal dialysis related peritonitis, one of the most serious, highly complicated and high mortality associated infection for CAPD patients. • Mean peritoneal dialysate concentrations after intraperitoneal administration of daptomycin at a dose of 6mg/kg BW were multiple times higher than the minimum inhibitory concentrations (MIC) range (therapeutic index) for all the other strains of Staphylococcus spp., β- hemolytic streptococci and Corynebacterium Jeikeium and for the majority of the selected gram-positive anaerobic organisms. Similarly, the Inhibitory Quotient (Cmax/MIC90) peritoneal dialysate values were very high for each one of the previously mentioned aerobic bacteria and for the majority of the anaerobic pathogens, indicating that intraperitoneal dosing of Daptomycin at 6 mg/kg BW every 48 hours seems to be effective in treating peritoneal dialysis related infections due to these gram-positive organisms. • Both intravenous and intraperitoneal dosing of daptomycin at a dose of 6mg/kg BW achieved lower concentrations in peritoneal dialysate than the breakpoints for all strains of Enterococcus spp. Given the exceptional in vitro activity of Daptomycin against Enterococci, Vancomycin-Resistant strains included, it is strongly recommended that such infections in CAPD patients should be treated with intraperitoneally administered Daptomycin at higher doses, greater than 8 mg/mL BW. • Regarding Daptomycin’s toxicity, it has been reported that it is correlated to the Daptomycin plasma minimum concentrations exceeding the threshold of 24,3 μg/mL. In this study the minimum plasma concentrations were much lower, regardless the route of administration. These were 10.32 μg /mL at 24 hours and 3,93 μg/mL at 48 hours after IV administration and 8.41 μg /mL at 24 hours and 3.6 μg /mL at 48 hours after IP administration, indicating absence of toxicity with the used dose of 6 mg/Kg BW • The above pharmacokinetic and pharmacodynamic data suggest that the IV administration route of Daptomycin at a dose of 6mg/kg BW is far from optimal regarding the treatment for peritoneal dialysis-related peritonitis, due to the very low peritoneal penetration rate from plasma to peritoneal cavity. Intravenously administered Daptomycin may be effective in cases of systemic infections or complicated skin and soft tissue infections, such as peritoneal catheter exit-site infections. • In contrast, intraperitoneally administered Daptomycin at a dose of 6 mg/kg BW resulted in satisfactory plasma concentrations due to its high penetration rate through the peritoneal membrane, from the peritoneal dialysate to plasma, and can be used as an alternative route of administration for the treatment of systemic infections caused by susceptible organisms. • The intraperitoneal route of Daptomycin administration should be preferred, against the intravenous route, for the treatment of peritoneal dialysis-related peritonitis in CAPD patients. Intraperitoneal dosing of daptomycin at a dose of 6 mg/kg BW in a 6-hour dwell results in high concentrations in the peritoneal dialysate, achieves effective exposure for up to 48 hours in most cases, and demonstrates adequacy and efficacy for the treatment of peritoneal dialysis-related peritonitis caused by the most common gram-positive organisms. In the treatment of difficult to treat and potentially life-threatening infections, such as peritoneal dialysis-related infections in CAPD patients, the selection of optimal antibiotic dosing based on pharmacokinetic and pharmacodynamic parameters might be crucial for the success of the therapeutic scheme.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2020
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Divanis, Dimitrios
- Διβάνης, Δημήτριος
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/47594